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ABSTRACT 
Abibalsamins A (1) and B (2), two unprecedented tetraterpenoids featuring a 3,4-seco-rearranged lanostane system 
fused with a β-myrcene lateral chain via a [4 + 2] Diels-Alder cycloaddition, were isolated from the oleoresin of Abies 
balsamea. Their structures were elucidated by means of extensive 2D NMR, IR and MS spectroscopy analyses. The 
absolute configuration of 1 was determined by single-crystal X-ray diffraction. Both compounds exhibited significant 
cytotoxic activity against cancer cell lines. 
The genus Abies (Pinaceae) consists of 46 species, 
which are mainly distributed in temperate and boreal 
regions of North and Central America, Europe, Asia and 
North Africa.1 Previous investigations on the chemical 
composition of firs (Abies) led to the identification of 
several secondary metabolites such as triterpenoids, 
flavonoids, stilbenes, chalcones and lignans, some of 
them exhibiting pharmaceutically relevant biological 
activities.2-4 
Balsam fir-Abies balsamea (L.) Mill. is widely 
distributed in the eastern part of Canada. Traditionally, it 
has been used as an antiseptic, tuberculosis remedy and 
venereal aid.5 Balsam fir, like other true firs, is 
characterized by the presence of blisters on the surface of 
young bark that contain an aromatic liquid called the 
cortical oleoresin. Oleoresin is known as a complex 
mixture of mono-, sesqui-, di- and triterpenoids.6-9 
Aboriginal people in Canada have employed fir oleoresin 
as a vulnerary, although nowadays its main field of 
utilization is as a cement for lenses and as mounting 
medium in microscopy.10 
In the course of our research program aiming at the 
isolation and identification of bioactive substances from 
plant species of Quebec’s boreal forest,11-13 we have 
become interested in studying the constituents of A. 
balsamea.12,14-16 This work led to the isolation of two new 
 
tetraterpenoids, abibalsamins A (1) and B (2), which 
features an unusual 3,4-seco rearranged lanostane 
triterpene fused with a β-myrcene moiety. The closely 
related abiesonic acid (3)17 was isolated as well. In this 
Letter, we report the isolation, structural elucidation and 
absolute configuration of the new compounds 1 and 2 
(Figure 1) based on spectroscopic data, X-ray 




Figure 1. Structures of abibalsamins A (1) and B (2), and the 
related abiesonic acid (3). 
 
The oleoresin of A. balsamea (500 g)18 was directly 
subjected to silica gel column chromatography eluting 
with hexanes/EtOAc as a gradient (100:0 to 93:7), then 
MeOH. Both hexanes/EtOAc 93:7 and MeOH fractions 
were combined and concentrated under reduced pressure 
(75 g). A portion of the extract (60 g) was further 
fractionated on silica gel using a gradient of 
hexanes/EtOAc, affording three subfractions A-C. 
Subfraction B was purified by silica gel with 
hexanes/EtOAc (3:1), giving five other subfractions A'-E'. 
Repeated column chromatography of subfraction C' on 
C18 reversed-phase with H2O/MeOH (1:4 to 0:1) followed 
by purification by preparative HPLC yielded compounds 
1 (44.6 mg) and 2 (13 mg). Crystals of 1 were obtained by 
recrystallization with EtOH. Purification of subfraction E' 
on polyamide column followed by preparative HPLC 
separation yielded 3 (10 mg), which was identified as 
abiesonic acid after spectral caracterization (IR, NMR, 
MS).17 This compound has been thoroughly described in 
literature in the form of a dimethyl ester.8,19 
Compound 1, [α]20D -24.8 (c 0.9, CHCl3), showed a 
pseudomolecular ion peak at m/z 619.4348 [M + H]+ in 
the HRESIMS suggesting the molecular formula 
C40H58O5. IR absorptions band at 1702 (s) cm-1 implied 
the presence of carbonyl functionality. Analysis of 13C 
NMR data and HSQC spectrum revealed the presence of 
seven methyls, twelve sp3 methylenes, four sp3 methines, 
four sp3 quaternary carbons, two sp2 methylenes, three sp2 
methines and eight sp2 quaternary carbons. A close 
comparison of carbon chemical shift of 1 with abiesonic 
acid (3) suggested a 3,4-seco-rearranged lanostane system 
with a lateral chain constituted of an additional 6-
membered ring. Analysis of the COSY spectrum revealed 
four spin systems (Figure 2) on the lateral chain which 
were connected by HMBC cross-peaks from H3-21 to C-
17, C-20 and C-22, from H2-22 to C-23, from H-24 to C-
23, from H3-27 to C-24, C-25, C-26 and C-31, from H-32 




Figure 2. Selected 1H-1H COSY, HMBC and ROESY 
correlations for compound 1. 
 
The relative stereochemistry was established with the 
ROESY spectrum where cross-peaks from H-28Z to H-9 
and from H3-19 to H-9 and H3-29 were observed (Figure 
2). These facts indicated that H-5, Me-19 and H-9 are 
positioned ,  and , respectively. Other correlations 
were observed between H3-18/H-7 and H-30/H-1 
suggesting that ring D is connected in such a way that C-
17 is -oriented and Me-18 is also . The stereochemistry 
of the lateral chain could not be established 
unambiguously with the ROESY spectrum. Single-crystal 
X-ray diffraction analysis was carried out in order to 
confirm the structure of 1 (Figure 3). The absolute 
configuration was determined by Flack’s method with 
Flack’s parameter determined as 0.0(2).20 The X-ray 
structure demonstrated that the chiral centers in 1 were 
5S, 9S, 10S, 13R, 17S, 20R, 24S and 25S. Furthermore, 
the ROESY correlation between H-28Z and H-24 could 
be better understood since the measured separation 
distance was 2.88 Å. On the basis of these spectroscopic 




and named abibalsamin A.21 
 
 
Figure 3. X-ray structure of abibalsamin A (1). 
 
Compound 2, [α]20D -44.5 (c 1.0, CHCl3), showed a 
pseudomolecular ion peak at m/z 633.4514 [M + H]+ in 
the HRESIMS suggesting the molecular formula 
C41H60O5. IR absorptions band at 1737 and 1708 (s) cm-1 
implied the presence of carbonyl functionalities. 
Comparison of the 1H and 13C NMR spectra with those of 
compound 1 revealed that they differ only by an 
additional methyl group linked at one of the carboxylic 
functionalities. An upfield shift at C-3 (6.4 ppm) for 2 
along with a HMBC correlation between the new OCH3 
group and C-3 were observed and allowed us to assign the 














Table 1. NMR data of compounds 1 and 2 (δ in ppm, J in Hz) 
no. 
1 2 
δH δC δH δC 
1 1.68, m (2H) 
 
29.7 1.63, m 
1.76, m 
30.7 
2 2.34, m (2H) 28.7 2.31, m (2H) 29.3 
3 - 181.3 - 174.9 
4 - 149.4 - 149.3 
5 2.05, m 43.9 2.07, m 44.0 
6 2.14, m 
2.34, m 
31.1 2.14, m 
2.39, m 
31.0 
7 5.43, br s 122.2 5.45, br s 122.1 
8 - 144.0 - 143.7 
9 2.15, m 49.2 2.17, m 49.2 
10 - 37.3 - 37.0 
11 1.34, m 
1.67, m 
22.4 1.39, m 
1.64, m 
22.5 
12 1.26, m 
1.66, m 
31.3 1.31, m 
1.75, m 
31.2 
13 - 63.6 - 63.5 
14 - 161.7 - 161.5 
15 2.35, m 
2.47, m 
28.0 2.36, m 
2.47, m 
27.9 
16 1.54, m (2H) 36.5 1.56, m (2H) 36.4 
17 - 50.5 - 50.4 
18 0.87, s 18.0 0.89, s 18.0 
19 0.93, s 25.0 0.94, s 24.9 
20 2.31, m 33.1 2.33, m 33.9 
21 0.81, d (6.5) 17.0 0.80, d (6.4) 16.6 
22 2.12, m 
2.36, m 
44.6 2.14, m 
2.30, m 
44.7 
23 - 211.5 - 211.4 
24 3.12, dd (12.4, 5.1) 50.4 3.08, dd (11.8, 5.4) 50.4 
25 - 42.5 - 42.3 
26 - 185.0 - 183.6 
27 1.29, s 15.7 1.25, s 16.1 
28 Z 4.92, br s 111.7 4.83, s (2H) 111.9 
 E 4.82, s    
29 1.78, s 26.5 1.77, s 26.3 
30 E 4.76, s 106.8 E 4.76, s 106.7 
 Z 4.67, br s  Z 4.72, br s  
31 2.01, m 
2.28, m 
38.1 2.05, m 
2.33, m 
37.6 
32 5.39, d (3.8) 118.8 5.39, br s 118.9 
33 - 135.8 - 135.4 
34 1.87, m 
2.22, m 
29.0 1.87, m 
2.27, m 
28.7 
35 2.06, m (2H) 37.1 2.03, m 
2.08, m 
37.1 
36 2.10, m (2H) 26.3 2.09, m (2H) 26.3 
37 5.07, t (6.7) 123.7 5.06, t (5.9) 123.8 
38 - 131.9 - 131.9 
39 1.68, br s 25.7 1.68, br s 25.7 
40 1.61, br s 17.8 1.60, br s 17.8 
Me - - 3.67, s 51.6 
* 
Although some marine species have been shown to 
contain polycyclic tetraterpenoids,23-25 the isolation of 
non-carotenoid C40 compounds from plants is very 
scarce.26 A plausible biosynthetic pathway of 
abibalsamins A (1) and B (2) is proposed in Scheme 1. In 
opposition to ‘true’ tetraterpenes such as the carotenoids, 
which are formed by a head-to-head condensation of two 
geranylgeranyl pyrophosphate (GGPP) units,27 it is likely 
that abibalsamins 1 and 2 would come from a different 
biosynthetic route. Since abiesonic acid (3), a 3,4-seco-
rearranged lanostane-type triterpenoid,28 as well as the 
monoterpene β-myrcene have previously been isolated 
from A. balsamea,29 it seems reasonable to propose that 
abibalsamin A (1) would be formed by an enzyme-
catalyzed [4 + 2] Diels-Alder-like cycloaddition between 
3 and β-myrcene. Abibalsamin B (2) would then be 
obtained by the esterification of C-3 carboxylic acid 
function in 1. Such a type of Diels-Alder-like biosynthetic 
reaction has already been suggested for dimeric 
triterpenoids30 and tricyclic spirolactones,31 to name a few 
recent examples. 
 




Table 2. Cytotoxic activity of compounds 1-3a 
Cancer cells lines Compounds 
1 2 3 etoposide 
A549 22 ± 4 8.5 ± 0.7 22 ± 3 0.3 ± 0.1 
DLD-1 >100 15 ± 1 >100 1.0 ± 0.4 
WS1 >100 14.7 ± 0.2 30 ± 2 5 ± 1 
a IC50 in μM. 
 
The in vitro antiproliferative activities of compounds 1-
3 against lung carcinoma (A549), colorectal 
adenocarcinoma (DLD-1) and normal skin fibroblasts 
(WS1) human cell lines were evaluated using the 
resazurin reduction test as previously described.32 The 
cytotoxicity results presented in Table 2 are expressed as 
the concentration inhibiting 50% of the cell growth (IC50). 
Etoposide was used as a positive control in this assay 
(IC50 0.3-5 μM). The most cytotoxic compound was 
abibalsamin B (2) with IC50 values of 8.5 ± 0.7 and 15 ± 1 
μM against A549 and DLD-1 cancer cell lines, 
respectively. Interestingly, abibalsamin A (1) selectively 
inhibit the growth of A549 cells (IC50 22 ± 4 μM) 
compared to DLD-1 and WS1 (IC50 >100 μM). 
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